Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 811 participants.

Also called NCT01499095

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 811 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01499095
  • EudraCT 2010-023770-39
Main results
  • New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2) Diabetes care, 2014-12 DOI, PubMed 25193531
Other papers using this trial's data
  • Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension Diabetes, obesity & metabolism, 2015-12 DOI, PubMed 26172084, PMC5049622 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Chile, Finland, France, Germany, Hungary, Mexico, Portugal, Romania, Russia, South Africa, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01499095. Randomized; no masking; primary purpose treatment. Start 2011-12 (registry gives no type); primary completion 2013-04 (actual). Results posted on 2015-04-23.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Acronym
EDITION II
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Lantus (Insulin glargine)
Intervention (Drug)
HOE901-U300 (new formulation of insulin glargine)
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct01499095
Content hash
14fbfcdd7b9003aa2c36f41791e913e1140546e48c3dc6fb12d257b5c30cd244